Catalent Implements Optofluidic Platform for Cell-Line Development

July 12, 2018

Catalent Biologics will adopt Berkeley Lights’ Beacon optofluidic platform for its cell-line development workflow.

Catalent Pharma Solutions and Berkeley Lights announced in a July 10, 2018 press release that Catalent Biologics will adopt Berkeley Lights’ Beacon optofluidic platform for its cell-line development workflow.

The Beacon platform is capable of screening thousands of clones in parallel and identifying top-producing clones in five days. According to Catalent, automating the process on the platform provides additional insights into the behavior of clonal populations that are currently unavailable using traditional techniques. 

The four integrated workflows of the platform-import, culture, assay, and export-will be applied to Catalent Biologics’ GPEx cell-line development platform as well as Catalent’s ongoing research and development activities.

Source: Catalent Pharma Solutions